ProMIS Neurosciences Beta
Cos'è Beta di ProMIS Neurosciences?
Beta di ProMIS Neurosciences, Inc. è 0.71
Qual è la definizione di Beta?
BETA indica se una azione è più o meno volatile rispetto al mercato nel suo complesso. Un beta inferiore a 1 indica che la azione è meno volatile rispetto al mercato, mentre un beta più di 1 indica che la azione è più volatile. La volatilità è misurata come la fluttuazione del prezzo attorno alla media.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta di aziende nel Health Care settore su TSX rispetto a ProMIS Neurosciences
Cosa fa ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Aziende con beta simili a ProMIS Neurosciences
- Hindustan Zinc ha Beta di 0.71
- China Tangshang ha Beta di 0.71
- Liberty Shoes ha Beta di 0.71
- Hing Lee (HK) ha Beta di 0.71
- One World Universe Inc ha Beta di 0.71
- Amrutanjan Health Care ha Beta di 0.71
- ProMIS Neurosciences ha Beta di 0.71
- Aberdeen Emerging Markets Investment Co ha Beta di 0.71
- Alerus ha Beta di 0.71
- Ashland Inc ha Beta di 0.71
- Oriola Oyj ha Beta di 0.71
- PI Industries ha Beta di 0.71
- PVV Infra ha Beta di 0.71